Background: Because of a change in lifestyle, especially adoption of westernized eating habits, lifestyle-related diseases have become increasingly prevalent. The aim of this study was to investigate the association of medications for lifestyle-related diseases with reflux esophagitis (RE). Methods: We conducted a hospital-based, cross-sectional retrospective study of consecutive outpatients who received an upper gastrointestinal endoscopy in our department from February 2008 to November 2014, which was performed by one specialist who was a member of the Japan Gastroenterological Endoscopy Society. We investigated the patient profile, Helicobacter pylori (H. pylori) infection status, medications for lifestyle-related diseases (including calcium channel blockers, statins, and bisphosphonates), and upper gastrointestinal endoscopic findings (RE, hiatal hernia, Barrett's mucosa, and endoscopic gastric mucosal atrophy [EGA]). Patients with gastrectomy, peptic ulcer disease, gastric or esophageal malignant disease, and those who used proton pump inhibitors or histamine-2 receptor antagonists were excluded. We divided the subjects into a group without RE (RE(-)) and a RE (RE(+)) group as judged by endoscopy, and investigated the risk factors for RE. Results: Of 1,744 consecutive cases, 590 cases (300 males and 290 females; mean age 60.5±13.2 years) were eligible. RE(-) and RE(+) cases numbered 507 and 83, respectively. Bivariate analysis showed significant positive associations of RE with male sex, body mass index (BMI), calcium channel blockers, Barrett's mucosa, hiatal hernia and negative associations of RE with H. pylori positivity, EGA. Multivariate analysis showed significant positive associations of RE with BMI (odds ratio Conclusion: Calcium channel blockers were positively associated with RE and statins were negatively associated with RE, while bisphosphonates were not associated with RE.
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Introduction
Because of a change in lifestyle, especially adoption of westernized eating habits, metabolic syndrome and lifestyle-related diseases such as hypertension, dyslipidemia, diabetes, and osteoporosis have become a significant public health problem in Japan. These diseases are closely associated with reflux esophagitis (RE). [1] [2] [3] These lifestylerelated diseases increase the risk of death and reduce the quality of life and life expectancy. Consequently, there is an increase in national cost of medical care, which highlights that preventive therapy for lifestyle-related diseases are very important.
Dovepress
asaoka et al
With regard to the association between RE and medications for lifestyle-related diseases, calcium channel blocker use might affect lower esophageal sphincter pressure, while bisphosphonate use has been associated with esophagitis in Western countries. 5, 6 The pleiotropic effects and therapeutic potential of statins in gastrointestinal tract disorders have also been reported. 7 However, there are few reports relating to the association between RE and medications for lifestyle-related diseases in Japan. 8 Furthermore, most previous reports concerning the risk factors for RE have included subjects who were taking gastric acid secretion inhibitors such as proton pump inhibitors (PPI) or histamine-2 receptor antagonists (H2RA) that may affect the development of RE. Therefore, the risk factors for RE should be investigated in patients who are not taking PPI or H2RA. The aim of this study was to investigate the association of medications for lifestyle-related diseases with RE.
Methods
We conducted a hospital-based, cross-sectional retrospective study of consecutive outpatients who received an upper gastrointestinal endoscopy in our department from February 2008 to November 2014, which was performed by one specialist (DA) who was a member of the Japan Gastroenterological Endoscopy Society. Subjects were included if information on all of the following aspects were available in the medical records: patient profile (age, sex, body mass index [BMI] , cumulative alcohol intake [kg] , and Brinkman index); Helicobacter pylori (H. pylori) infection status (negative, positive, or negative after eradication therapy); medications for lifestyle-related diseases (including calcium channel blockers, statins, and bisphosphonates); and findings of upper gastrointestinal endoscopy (RE, hiatal hernia, Barrett's mucosa, and endoscopic gastric mucosal atrophy [EGA]). BMI was calculated as body weight divided by the square of body height in meters (kg/m 2 ). The Brinkman index score was determined by the number of cigarettes smoked per day multiplied by the number of years of smoking. 9 Cumulative alcohol intake was defined as the cumulative intake of ethanol (kg). H. pylori infection status was assessed by the 13C-urea breath test 10 and/or serum antibodies to H. pylori. We defined a positive result for any of these tests as being positive for H. pylori infection. We also defined a negative after eradication result by the 13C-urea breath test as negative for H. pylori infection, 4-8 weeks after eradication therapy. We defined cases as users of a specific therapy who were taking a typical dose of calcium channel blockers, statins, or bisphosphonates for more than half a year. We investigated findings from upper gastrointestinal endoscopy (RE, Barrett's mucosa, hiatal hernia, and EGA). We defined RE as grade A, B, C, and D according to the Los Angeles Classification. Barrett's mucosa is defined as the area between the squamocolumnar junction and the esophagogastric junction. The esophagogastric junction was defined as the end of the inferior palisade vessel. When we could not detect the palisade vessel, we defined it as the proximal margin of the gastric fold. The squamocolumnar junction is recognized as the area that demarcates the "reddish" gastric epithelium from the "whitish" esophageal epithelium. Hiatal hernia was defined as an apparent separation of the esophagogastric junction and diaphragm impression by more than 2 cm at endoscopy. EGA was classified as C-0 (normal), C-1, C-2, C-3, O-1, O-2, or O-3 using the Kimura-Takemoto classification system, 11 which identifies the location of the endoscopic atrophic border. Overall, the EGA was scored as 0 for C-0 type, 1 for C-1 type, 2 for C-2 type, 3 for C-3 type, 4 for O-1 type, 5 for O-2 type, and 6 for O-3 type.
We excluded patients with the following: those who had gastrectomy, peptic ulcer disease, and gastric or esophageal malignant disease. Additionally, we also excluded patients who were currently or previously treated with agents affecting RE, including PPI or H2RA, in bivariate and multivariate analysis. This study was conducted in accordance with the tenets of the Declaration of Helsinki. The Juntendo University Ethics Committee approved the study and the study protocol (reference number . In regard to the informed consent of participants, the Juntendo University Ethics Committee made a decision based on the Ethical Guidelines for Medical and Health Research Involving Human Subjects that states that non-intervention studies are deemed exempt from patient's consent and instead researchers must notify the study subjects of the information about study contents on a homepage and guarantee the opportunity when the study subjects could refuse it. According to the decision of the Juntendo University Ethics Committee, we notified the study subjects of the information about our study contents on a homepage of our hospital and guaranteed the opportunity when the study subjects could refuse it.
statistical analysis
We divided the subjects into a group without RE (RE [-] ) and a group with RE (RE[+]), as judged by endoscopy. We then investigated the risk factors for RE, especially the association between RE and medications for lifestyle-related diseases, using bivariate and multivariate analysis. Multivariate logistic regression analysis was performed using a backward selection method (likelihood ratio). The odds ratio (OR) and 95% confidence intervals (CIs) were also used to identify the presence and strength of any associations. Standard techniques for 
Results
Clinical characteristics
Of the 1,744 consecutive investigated cases, 562 were excluded because of unknown status for H. pylori (379 cases), evidence of gastrectomy (97 cases), peptic ulcer disease (58 cases), and gastric or esophageal malignant disease (28 cases 
Bivariate analysis
Risk factors for RE (including users of gastric acid secretion inhibitors) in bivariate analysis are listed in Table 3 . Approximately 42.5% (448/1,055) of patients in the RE(-) group used PPI versus 24.4% (31/127) in the RE (+) group.
After excluding users of gastric acid secretion inhibitors, results of the bivariate analysis are listed in 
Discussion
This study showed that calcium channel blockers and statins as medications for lifestyle-related diseases were associated with the presence of RE, while bisphosphonates were not associated with the presence of RE. Furthermore, consistent with previous reports assessing the Japanese population, H. pylori infection, EGA, hiatal hernia, and Barrett's mucosa were also associated with RE. 1, 2, 36, 42 Previously, Hongo et al 5 reported that nifedipine significantly decreased lower esophageal sphincter pressure and contraction amplitude in the esophageal body; thus, it has been reported that calcium channel blockers may be useful as therapy for achalasia. 12 In patients with RE, Ishikawa et al 13 reported that duration of esophageal acid exposure after the administration of nifedipine was significantly longer compared with placebo. In this study, calcium channel blocker use was associated with the presence of RE, and a decrease in lower esophageal sphincter pressure might cause gastric acid reflux up the esophagus, resulting in a possible increase in RE. In those subjects who visited a medical center for their annual medical check-up, Niigaki et al 1 reported that subjects undergoing treatment for hypertension showed an increased risk of RE, while those with untreated hypertension were not statistically associated with prevalence of RE, 
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Medications of lifestyle-related diseases and reflux esophagitis although the details of their medical treatment could not be investigated.
However, it has been reported that several antihypertensive drugs have healing effects on the esophageal mucosa. 14 Miwa et al 15 reported that angiotensin II receptor blockers may act to promote healing of the esophageal mucosa. Further prospective studies are needed to elucidate the association between antihypertensive drugs (except calcium channel blockers) and the prevalence of RE.
In 1996, de Groen et al 6 demonstrated the association between esophagitis and the use of bisphosphonate. Although the pathogenesis of bisphosphonate-induced esophageal mucosal damage has not been clearly demonstrated, direct chemical esophageal damage with prolonged local mucosal exposure to a drug with gastric acid might be the most plausible biological mechanism as suggested by the literature. 16 However, the highest level of evidence, randomized controlled trials, suggests little or no increase in risk of upper gastrointestinal tract problems if bisphosphonates are administered properly. 16, 17 While pharmacists carefully instruct patients on the appropriate dosing regimen (taking a tablet with enough water and remaining upright for at least 30 minutes before the first food of the day) and patients tend to properly observe an internal use method in Japan, bisphosphonate use might be not associated with RE in this study. However, recognition of bisphosphonate-associated erosive or ulcerative esophagitis, and communication of this possibility to the clinician, may be important.
Recently, the pleiotropic effects of statins have been shown, with a demonstration of cholesterol-reducing effects, as well as anti-inflammatory action, antioxidative function, and ability to increase eNOS expression. According to recent reports, statins induce anti-inflammatory effects and demonstrate antioxidative function via inhibition of activation of 
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NADPH oxidase, as well as upregulation of eNOS expression through the PI3K-Akt pathway. [18] [19] [20] [21] In subjects who visited a medical center for their annual medical check-up, Niigaki et al 1 reported that the risk for subjects undergoing treatment for dyslipidemia was lower than those for subjects not undergoing such therapy, although the details of their medical treatment could not be investigated. It was reported that inflammatory cytokines, oxidative stress, and an eNOS expression decrease were associated with the pathophysiology of RE. [22] [23] [24] [25] Thus, the pleiotropic effects such as eNOS upregulation, antioxidative function, and anti-inflammatory action may play a crucial role in prevention of RE. On the other hand, previous studies have indicated that lower serum adiponectin levels are associated with various inflammatory diseases of the digestive system, [26] [27] [28] [29] [30] and it was reported that statins possess an adiponectin-increasing effect. 31 Thus, the adiponectin-increasing effect of statins may be associated with the preventive effect of RE.
Consistent with previous studies on the Japanese population, BMI was associated with the development of RE in this study. Gastric acid reflux due to increased abdominal pressure through obesity is the most plausible biological mechanism for the development of RE. Although we did not investigate the waist circumference and visceral fat area, it has been reported that the abdominal visceral adipose tissues can secrete some substances such as adipokines that are associated with the development of RE. 28 Male sex has also been reported to be an important predictive factor for RE. 32, 33 In this study, male sex was associated with the presence of RE in bivariate analysis, but was not associated with RE after multivariate analysis was performed. Since the number of study subjects was relatively small in this study, the inclusion of more cases may be necessary to truly ascertain whether there is a significant association between male sex and RE. Smoking affects esophageal defense mechanisms and decreases lower esophageal sphincter pressure. 34 Alcoholic beverages are associated with impairment of primary peristalsis and a decrease in lower esophageal sphincter (LES) pressure. 35 In this study, cumulative alcohol intake and the Brinkman index were not associated with the development of RE. Current alcohol intake and smoking might be more important for risk of RE than the quantity of alcohol and the Brinkman index, although we did not investigate current alcohol intake and smoking in this study.
H. pylori positivity and EGA had an inverse association with RE in our study. Generally, reflux of increased acid contents is associated with the development of RE. 36, 37 The potential mechanisms behind the inverse association with RE may be due to neutralization of acid by ammonia generated by H. pylori organisms and decreased acid secretion as a consequence of corpus atrophy. 38 Consistent with previous studies of the Japanese population, hiatal hernia and Barrett's mucosa were associated with RE in this study. 32, [39] [40] [41] [42] This study had several limitations. It was a hospitalbased, single-center, cross-sectional retrospective study of consecutive outpatients who received an upper gastrointestinal endoscopy in our department. Furthermore, this procedure was conducted by one specialist who was a member of the Japan Gastroenterological Endoscopy Society; therefore, the data might not represent the general population. Furthermore, it might not be possible to fully evaluate the cause and effect association between RE and medications for lifestyle-related diseases. The sample size of this study was relatively small; therefore, further larger, multicenter prospective studies will be needed to clarify the true association between RE and prescribed medications for lifestyle-related diseases. Second, we could not evaluate the details of prescribed therapeutic drugs for diabetes mellitus, 
Conclusion
We identified that calcium channel blockers and statins as medications for lifestyle-related diseases were associated with the presence of RE, while bisphosphonates were not associated with the presence of RE. As eating habits become more westernized, the prevalence of lifestyle-related diseases has increased in Japan, resulting in a significant public health problem. It may be useful to clarify the association of medications for lifestyle-related diseases with RE, as well to further elucidate the best medical treatment for RE.
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